Hemab Therapeutics Secures $157M Series C Funding to Advance Rare Blood Disorder Treatments
Hemab Therapeutics, a biotech company focused on developing treatments for rare and underserved bleeding disorders, has successfully raised $157 million in a Series C funding round. The financing, led by Sofinnova Partners, will support the advancement of Hemab's pipeline and clinical candidates for conditions such as Glanzmann thrombasthenia and von Willebrand disease.
Funding Details and Investor Participation
The oversubscribed Series C round saw participation from both existing and new investors. Alongside lead investor Sofinnova Partners, the funding effort included contributions from:
- Existing investors: Novo Holdings, RA Capital Management, and Rock Springs Capital
- New investors: Qatar Investment Authority and Avoro Capital Advisors
- An unnamed large global asset management company
Dr. Benny Sorensen, CEO of Hemab Therapeutics, stated, "The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company."
Clinical Programs and Development Strategy
Hemab's clinical pipeline is centered on two key assets:
Sutacimig for Glanzmann Thrombasthenia
Sutacimig, a midstage asset, is being developed as the first prophylactic treatment for Glanzmann thrombasthenia, a rare genetic bleeding disorder. The drug candidate, a subcutaneously administered bispecific antibody, has shown promising results in Phase 2 studies, achieving clinically meaningful bleeding reduction.
- Mechanism of action: Mimics the function of factor VIIa while targeting activated platelets at bleeding sites
- Next steps: Planned evaluation in Factor VII deficiency in the coming year
HMB-002 for Von Willebrand Disease
HMB-002 is a monovalent antibody designed as a bleeding prophylactic for patients with von Willebrand disease. Early data indicate that the drug can directly target the underlying pathophysiology of the disease by increasing both Von Willebrand Factor and Factor VIII levels.
- Dosing goal: Hemab is aiming for once-monthly administration
- Future plans: The new funding will support the advancement of HMB-002 into a registration study
Expansion and Future Outlook
Hemab's ambitious growth strategy, dubbed the "1-2-5" concept, aims to advance five development projects by 2025. The company's pipeline currently lists sutacimig and HMB-002, with plans to introduce additional candidates into clinical development, including a prospect called HMB-003 in 2026.
Dr. Joe Anderson, partner at Sofinnova Partners and new board member of Hemab, highlighted the company's "deep scientific excellence and strong clinical execution," calling it a "standout company in the biotech landscape."
As Hemab continues to build its portfolio, the company emphasizes a technology-agnostic approach, selecting optimal scientific strategies for each specific condition it targets. This precision approach utilizes "targeted solutions rather than generic approaches," according to the company's website.
References
- Hemab collects another $157M to go after ‘underserved’ blood diseases
The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation disorders company,” its CEO said.
- Hemab, working to build 'ultimate clotting company,' raises $157M series C for bleeding disorder ambitions
The company will use the fresh funding to build out its pipeline and advance its clinical candidates for Glanzmann thrombasthenia and von Willebrand disease.
Explore Further
What are the projected timelines for Hemab's pipeline assets like sutacimig and HMB-002 to achieve regulatory approval?
What is the target market size for rare bleeding disorders such as Glanzmann thrombasthenia and von Willebrand disease?
Who are the key competitors developing treatments for rare bleeding disorders, and how do their pipelines compare to Hemab's assets?
What are the clinical data highlights for sutacimig and HMB-002 that differentiate them from existing or experimental treatments in this space?
What is Hemab’s strategy for expanding its '1-2-5' growth concept, and how will funding support pipeline development beyond 2025?